Created On: 2020-07-15
Record Count: 7
- ribonucleic acid
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279354
Licensor grants to Licensee (a) an exclusive license to use in any country of the world any method or composition claimed by the Licensor Patents, and (b) a non-exclusive license to use in any country of the world any Licensor Know-How, to research in the Field Lead Compounds, Development Compounds, Backup Compounds, and Licensed Products.
Licensor Patents means a) the patents and applications listed; b) any application that claims priority to the foregoing patents and applications; and c) any patent that issues from any of the applications described in clauses a) and b) above.
US Patent #6,506,559 – Genetic inhibition by double-stranded RNA
US Patent #6,117,657 – Non-nucleotide containing enzymatic nucleic aci
US Patent #6,586,238 – Enzymatic nucleic acids containing 5-and or 3-cap structures
Lead Compound is a Lead selected by JSC for evaluation in the Field.
Development Compound means a Pre-Development Compound that the JSC has designated for clinical development.
Compound means a composition comprising one or more siNAs as active ingredients, known as of the Effective Date or discovered pursuant to this Agreement subsequent to that date, against the Licensee Named Targets in the Field.
Backup Compound means a Lead Compound that the JSC has selected as a backup candidate for clinical development.
JSC means the Joint Steering Committee.
Licensee is to develop Sirna-027, a RNAi-based therapeutic currently in Phase 1 for age-related macular degeneration (AMD), and to discover and develop other RNAi-based therapeutics against select gene targets in ophthalmic diseases.
IPSCIO Record ID: 294285
For the Non-Exclusive Research Licenses, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, to use solely for research done by Licensee or its Affiliates or by Third Party contractors for Licensee or its Affiliates the Licensor Technology, excluding any Licensor Technology that is now or hereafter during the Term covered by claims in issued patents or published patent applications disclosed to Licensee during the Term.
Applicable Biomolecule means a Biomolecule as to which Licensor at any time during the Term commenced IND-enabling toxicity studies or clinical trials.
Product means any product, including any pharmaceutical product or diagnostic product, which contains any Biomolecule, either alone or in combination with any other active pharmaceutical ingredient, in all formulations and strengths for all uses.
Combination Product means any pharmaceutical product containing a Biomolecule and one or more other active phannaceutical ingredients.
Licensee has extensive experience and expertise in the development and commercialization of pharmaceutical products. Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.
IPSCIO Record ID: 266725
— an exclusive license under the Licensor UsiRNA Technology IP and Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, and have improved the Collaboration Targets, the Collaboration Molecules, the Collaboration Candidates and the Collaboration Compounds in the Field and in the Territory; and
— a non-exclusive license under the Licensor Formulation Technology IP, UNA Platform Technology IP, and any improvement thereof made by Licensor related to the Collaboration Molecules, Collaboration Candidates and/or Collaboration Compounds, to use, have used, develop, have developed, improve, and have improved Licensees synthesis process, process development and manufacturing process in accordance with the Joint Research Plan in the Field and in the Territory.
Licensor grants, after selection of the Lead Compound and the Backup Lead,
— an exclusive license under the Licensor UsiRNA Technology IP, and any improvement thereof made by Licensor, and Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Lead Compound and Backup Lead in a Product in the Field in the Territory; and
— a non-exclusive license under the Licensor Formulation Technology IP and UNA Platform Technology IP, and any improvement thereof related to the Lead Compound, Backup Lead and/or Product made by Licensor through Licensees completion of the Development Plan, to use, have used, develop, have developed, improve, and have improved Licensees synthesis process, process development and manufacturing process and to make, have made, use, have used, manufacture, have manufactured, sell, distribute, export and/or import the Product anywhere in the Territory in the Field, and,
— all exclusive license under the Licensors rights and interest in the Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds, in the Exclusive Field in the Territory, and,
— a non-exclusive license under the Licensors rights and interest in the Joint UsiRNA Technology IP to search, have searched, develop, have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds in the Other Field in the Territory, and,
— an exclusive license under the Licensor UsiRNA Technology IP and any improvement thereof made by Licensor to search, have searched, develop, have developed, improve, have improved, register, have registered, make, have made, use, have used, market, store, package, label, sell, distribute, export and import the Backup Compounds, in the Exclusive Field in the Territory during the Non-Compete Period.
For the Diagnostic Tool;
— Licensor grants a non-exclusive license to develop, have developed, register, have registered, commercialize and have commercialized a Diagnostic Tool solely to the siRNA sequences disclosed in the Licensor UsiRNA Technology IP, in the Field and in the Territory, and,
— Licensor grants to Licensee a non-exclusive license under the Licnsors rights and interest in the Joint UsiRNA Technology IP to develop, have developed, register, have registered, commercialize and have commercialized a Diagnostic Tool, in the Field and in the Territory. For purposes of clarity, such non-exclusive license shall not include any rights to the UNA Platform Technology IP.
For manufacturing, the Swiss Licensee shall have the exclusive right to manufacture, or have manufactured the Lead Compound, the Backup Lead and the Product.
The patents include Formulation Technology IP; UNA Platform Technology IP; and Licensor UsiRNA Technology IP.
Diagnostic Tool means any companion diagnostic and/or any diagnostic assay relating to the Product.
The Exclusive Field means all uses in humans and animals for the prevention and treatment of superficial bladder cancer.
The Other Field means all uses in humans and animals, including but not limited to the prevention and treatment of diseases and other conditions in all indications excluding the Exclusive Field.
The Parties will work together to advance to market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer.
IPSCIO Record ID: 289173
The Parties shall direct their respective counsel to execute Stipulations of Dismissal with Prejudice dismissing all claims and counterclaims that were or could have been asserted in the Massachusetts State Court Action, U.S. Infringement Action, Canadian Infringement Action, and B.C. Action, and in the case of the Interference Proceeding, a Request for Adverse Judgment providing that Licensee concedes priority to Party A with respect to all claims that correspond to Counts 1-5, i.e., claims 34, 36, 38, and 40-43 of Party A U.S. Application 11/807,872; claims 1-6, 8, 10, 12-18, 21-22, and 32-33 of Licensee U.S. Patent 7,718,629; and claims 32-38 of Licensee U.S. Application 13/165,568, and requesting that an adverse judgment be entered against Licensee as to these claims and priority be awarded to Party A for U.S. Application 11/807,872.
Patent certains to intellectual property (IP) elements related to lipid nanoparticle (LNP) technology for RNAi therapeutics.
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.
IPSCIO Record ID: 280846
Licensee grants a non-exclusive grant back to Licensor of the Research Program Technology.
The research is to discover and develop RNA Targets and to conduct activities to discover Collaboration Compounds in the Licensees Field.
The Licensor has proprietary technology and experience in identifying therapeutically attractive drug targets in structural RNA and in designing and optimizing drug leads to bind to such targets.
IPSCIO Record ID: 300745
For the Manufacturing License, Licensor grants a non-exclusive license under Licensor Technology solely for the purpose of Manufacturing the Licensed Product for the Licensee Territory and Licensee grants Licensor a non-exclusive license under Licensee Technology to Manufacture the Licensed Product.
Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression.
The patents include, but are not limited to; RNA interference is mitigated by 21 and 22nt small RNAs; RNA interference mediating small RNA molecules; RNA sequence-specific mediators of RNA interference; and, Inhaled treatment for RSV.
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract.
IPSCIO Record ID: 294284
For the License, upon exercise of each specific option the German Licensor shall grant a non-exclusive license under German IP in accordance with the terms and conditions specified. Licensor agrees to grant a non-exclusive and worldwide license with the right to sub-license at terms and conditions consistent with this Agreement under the Licensor IP and the know-how relating to the atuRNAi(s) to research, develop, have developed, manufacture, have manufactured, market and sell Licensee Products.
atuRNAi(s) shall mean the siRNAs developed by or for Licensor and supplied to Licensee under this Agreement as potential inhibitors of certain molecular drug targets for therapeutic intervention.
Licensee IP means the present and future Patent Rights and Know-How owned by Licensee and directed to the [polypeptides, to nucleic acids encoding the polypeptides, antibodies to the polypeptides, antisense and siRNAJ to the Licensee Target genes and methods of treatment of diseases using these, including but not limited to rights to patents and patent applications.
Licensee Products means Products and Drug Products for the treatment of human diseases covered by Licensee IP.
The property includes Patent application EP 04010700.05 describing the use of lipids in formulations to deliver oligonucleotides into cells and tissues and all equivalent and derived applications including EP 02017601.2], and, PCT application number WO 2004/015107 and all equivalent/derived applications including US Provisional Application 60/402,541, the Licensors core technology patent application.
Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.
Ischemic injury is caused by diminished or absent blood flow. The main mechanism of injury in ischemia is hypoxia (as described above).